Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0

Chen, Alice; Setser, Ann; Anadkat, Milan J.; Cotliar, Jonathan; Olsen, Elise A.; Garden, Benjamin C.; Lacouture, Mario E.

doi:10.1016/j.jaad.2012.02.010

Cited by 250 publications

(215 citation statements)

References 27 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…Papulopustular acne-like eruption is the most common cutaneous adverse event (5) with an incidence rate of 55% (1). Xerosis, pruritus, desquamation, eczematous eruptions, teleangectasia, hyperpigmentation, trichomegalia, alopecia and nail alterations have also been reported (6)(7)(8). The present case report describes an atypical skin reaction in a patient treated with gefitinib.…”

Section: Introductionmentioning

confidence: 84%

Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature

Ferrazzi

Russo

Pasello

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor utilized for the treatment of advanced non-small cell lung carcinoma. The most commonly reported adverse event during gefitinib therapy is skin rash, particularly a papulopustular acne-like eruption. Cutaneous toxicities can affect treatment compliance and the quality of life of the patient. The present study reports a case of gefitinib-induced atypical skin reaction in a 73-year-old woman with advanced non-small cell lung cancer, who developed a squamous-crusted eruption on her face after 4 weeks of oral treatment with gefitinib at a dose of 250 mg/day. The patient was treated with 100 mg minocyclin (2 tablets/day, orally) and with ryfamicin topically. A complete resolution of the lesions was observed 2 weeks later. The present case report explored the pathogenesis of this skin manifestation, focusing on the underlying immunological mechanisms. A review of the literature concerning skin reactions to gefitinib was also conducted.

show abstract

Section: Introductionmentioning

confidence: 84%

Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature

Ferrazzi

Russo

Pasello

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Chemotherapy-associated toxicity was assessed according to the Common Terminology Criteria for Adverse Events, version 4.0, issued by the U.S. National Cancer Institute 14 . Adverse reactions are reported by grade (level of severity) on a scale of 1-5, with 1 being mild (no or mild symptoms, and no intervention required); 2 being moderate (some limitation of activities, with minimal local or noninvasive treatment required); 3 being severe (medically significant, but not immediately life-threatening; potentially requiring hospitalization or prolongation of existing hospitalization and posing limitations on personal activities of daily living); 4 being life-threatening (emergency treatment necessary); and 5 being patient death related to the adverse event.…”

Section: Evaluation Of Toxicitymentioning

confidence: 99%

Clinical Analysis of Osteosarcoma Patients Treated with High-Dose Methotrexate-Free Neoadjuvant Chemotherapy

2014

Current Oncology

View full text Add to dashboard Cite

(1) Objective: High-dose methotrexate (hdmtx) is a common therapeutic agent in the treatment of osteosarcoma. However, hdmtx is highly toxic and requires complex pharmacokinetic monitoring and leucovorin rescue. Thus, alternative therapeutic strategies are necessary. Here, we analyzed the clinical efficacy of a dia regimen (cisplatin–ifosfamide–doxorubicin) to evaluate its potential as an alternative to hdmtx–based therapy. (2) Methods: Patients received 12 cycles of chemotherapy administered over 2 years (2 preoperative cycles and 10 postoperative cycles). Cumulative dose was the same in all cycles: cisplatin 120 mg/m2 on day 1 of week 1, followed by ifosfamide 2.0 g/m2 days 1–5 of week 2, and doxorubicin 20 mg/m2 days 1–3 of week 2. (3) Results: Between January 2004 and October 2008, 39 eligible patients (median age: 16 years) were enrolled, with 36 being evaluable for the study. Of those 36 patients, 20 (55.6%) had a good histologic response to preoperative chemotherapy (>90% tumour necrosis). The estimated 5-year rates of event-free survival (efs) and overall survival were 54.8% and 61.5% respectively. (4) Conclusions: The results of our study suggest that, in osteosarcoma patients, the dia regimen produces an efs rate and survival outcomes comparable to those attained with hdmtx–containing regimens, with fewer adverse reactions. The dia regimen is well tolerated, and we observed a high level of patient compliance. Our results demonstrate that hdmtx-free osteosarcoma treatment regimens can be effective, warranting further investigation.

show abstract

“…No haemorrhagic cystitis, severe leucopenia, anaemia or thrombocytopenia (> 2 grade 'Common Terminology Criteria of Adverse Events Version 4Á0', CTCAE) occurred [26].…”

Section: Side Effectsmentioning

confidence: 99%

“…In four patients a temporary leucocyte count nadir was between 3Á9 and 3Á0 3 10 9/l after a median of 15 months, according to grade 1 of Common Terminology Criteria for Adverse Events (CTCAE) [26]. In one patient, MMF (2 3 500/day) was switched to MPA (2 3 360 mg/day).…”

Section: Side Effectsmentioning

confidence: 99%

Sequential therapy with cyclophosphamide and mycophenolic acid in patients with progressive immunoglobulin A nephropathy: a long-term follow-up

Rasche

Keller

Rasche³

et al. 2015

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryIn progressive immunoglobulin (Ig)A nephropathy (IgAN), cyclophosphamide pulse therapy (CyP), high-dose intravenous immunoglobulins (IVIg) and mycophenolic acid (MPA) have been used to stop progressive loss of renal function, but disease progression may occur after the end of the initial treatment. Here, we report the long-term follow-up of patients with progressive IgAN with MPA as maintenance therapy after CyP (CyP-MPA). In a median observation time of 6Á2 years, we analysed the slopes of the loss of renal function of 47 patients with biopsy-proven IgAN and treated with CyP. Thirtyone patients with further progression were treated with MPA maintenance for a median time of 5Á2 years. Follow-up was compared with symptomatic therapy and IVIg as historically matched control groups. Median loss of renal function was reduced significantly from 20Á9 ml/min to 20Á1 ml/min per month with CyP (P < 0Á05), and with MPA in patients with a relapse from 20Á4 ml/min to 20Á1 ml/min per month (P < 0Á05) until the end of the study. Proteinuria decreased significantly from 1Á6 g/l to 1Á0 g/l after CyP, and during MPA treatment to 0Á6 g/l (P 5 0Á001 Friedman test). Median renal survival time was in patients with CyP 10Á5 years (range 5 3Á2-17Á8), with CyP-MPA 10Á7 years (range 5 8Á3-13Á1), with IVIg 4Á7 years (range 5 2Á6-6Á6), and in untreated patients 1Á2 years (range 5 0Á8-1Á6; log-rank test P < 0Á01). In patients with progressive IgAN, our long-term follow-up observation indicates that sequential CyP-MPA therapy maintains renal survival significantly.

show abstract

Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0

Cited by 250 publications

References 27 publications

Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature

Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature

Clinical Analysis of Osteosarcoma Patients Treated with High-Dose Methotrexate-Free Neoadjuvant Chemotherapy

Sequential therapy with cyclophosphamide and mycophenolic acid in patients with progressive immunoglobulin A nephropathy: a long-term follow-up

Contact Info

Product

Resources

About